Small Cell Lung Carcinoma: all 1,234 studies

Page 3 of 13. Open to participants first (350), then studies with results posted, then the rest; newest registration first within each.

• A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNot yet recruitingNCT06614621Phase 2
• Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung CancerRecruitingNCT06613009Phase 1
• Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)RecruitingNCT06598306Phase 1
• Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLCNot yet recruitingNCT06597513Phase 1/2
• A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung CancerRecruitingNCT06592638Phase 1
• A Study With NKT3964 for Adults With Advanced/Metastatic Solid TumorsRecruitingNCT06586957Phase 1
• JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung CancerNot yet recruitingNCT06581380Phase 3
• Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung CancerRecruitingNCT06562920Phase 2
• Efficacy and Safety of Serplulimab With Chemotherapy and Aspirin in Untreated Extensive-Stage Small Cell Lung CancerNot yet recruitingNCT06554535Phase 2
• Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLCRecruitingNCT06536868Phase 2
• Radiotherapy Strategies for Use in Combined Treatment of Small-cell Lung CancerRecruitingNCT06529081Not applicable
• Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung CancerRecruitingNCT06527898Phase 1/2
• A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung CancerNot yet recruitingNCT06526624Phase 3
• Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung CancerRecruitingNCT06514118
• A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid TumorsRecruitingNCT06505824Phase 1
• 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer DetectionRecruitingNCT06503146Phase 2
• Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges MetastaticNot yet recruitingNCT06497543Phase 2
• Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLCRecruitingNCT06497530Phase 2
• Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLCRecruitingNCT06496048Phase 3
• Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized TrialRecruitingNCT06485544Phase 2
• Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer PatientsRecruitingNCT06481813Not applicable
• Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerRecruitingNCT06480864Not applicable
• Radiotherapy to All Residual Lesions After ChemoimmunotherapyRecruitingNCT06479473Phase 1/2
• A Study of Adebrelimab Combined With Chemoradiotherapy in the Treatment of Esophageal Small Cell CarcinomaNot yet recruitingNCT06478264Phase 2
• A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNot yet recruitingNCT06469879Phase 3
• Study on the Therapeutic Effect of Irinotecan Liposomes in Small Cell Lung CancerRecruitingNCT06467786Phase 4
• AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMARecruitingNCT06464068Phase 2
• Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung CancerNot yet recruitingNCT06462105Not applicable
• SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLCRecruitingNCT06457906Phase 3
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingNCT06440057Phase 1/2
• A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung CancerRecruitingNCT06437509Phase 2
• PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung CancerRecruitingNCT06429696Phase 2
• A Study of FZ-AD005 in Patients With Advanced Solid TumorsRecruitingNCT06424665Phase 1
• Phase 2 Study of Fingolimod in Lung CancersRecruitingNCT06424067Phase 2
• Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)Enrolling by invitationNCT06419179Phase 2
• A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
• Patient-derived Organoid Drug Sensitivity Guided Treatment for Recurrent Small Cell Lung CancerRecruitingNCT06406660Not applicable
• SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine CarcinomaRecruitingNCT06384482Phase 1
• PD-L1/PD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLCNot yet recruitingNCT06375109Phase 2
• Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)RecruitingNCT06371482Phase 2
• Efficacy and Safety of DEB-BACE Combined With Serplulimab in First-line Treatment of SCLCNot yet recruitingNCT06364046Not applicable
• Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With ImmunotherapyNot yet recruitingNCT06332950Phase 1/2
• A Real-world Study of Adebrelimab Combined With Chemotherapy±Chest Radiotherapy in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT06323265
• A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.Not yet recruitingNCT06306560Phase 2
• 177Lu-anti-PD-L1 sdAb in Metastatic Solid TumorsRecruitingNCT06305962Early Phase 1
• Serplulimab Combined With CCRT for LS-SCLC.RecruitingNCT06295926Phase 2
• Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scanEnrolling by invitationNCT06293833Not applicable
• Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingNCT06283719Phase 1/2
• Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLCRecruitingNCT06258642Not applicable
• Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 TrialRecruitingNCT06256237Phase 2
• Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung CancersRecruitingNCT06255197
• A Phase IIII Study of AL8326 in Small Cell Lung CancerRecruitingNCT06247605Phase 3
• A Study of MGC026 in Participants With Advanced Solid TumorsRecruitingNCT06242470Phase 1
• Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung CancerNot yet recruitingNCT06236997Phase 2
• Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)RecruitingNCT06228066Phase 2
• Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLCRecruitingNCT06223711Phase 2
• Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLCRecruitingNCT06217757Phase 1/2
• A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerRecruitingNCT06203210Phase 3
• Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapyRecruitingNCT06187740Phase 1
• A Phase Ⅱ Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLCRecruitingNCT06177925Phase 2
• Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor PrognosisRecruitingNCT06160596
• A Study of SGN-CEACAM5C in Adults With Advanced Solid TumorsRecruitingNCT06131840Phase 1
• Study of LY01610 in Patients With Recurrent Small Cell Lung CancerRecruitingNCT06128837Phase 3
• Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLCRecruitingNCT06125041Phase 2
• Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body IrradiationRecruitingNCT06110572Phase 1/2
• LOcally ABLatIve ThErapy for OligopRogressive Lung And Thoracic MalignanciEs (OBLITERATE)RecruitingNCT06103682Not applicable
• Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)RecruitingNCT06095583Phase 3
• A Study of Alisertib in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT06095505Phase 2
• A Study of Therapeutic Drug Monitoring-Based Atezolizumab DosingRecruitingNCT06066138Phase 1
• Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingNCT06047379Phase 1/2
• IN10018 Combination Therapy in Treatment-naïve ES-SCLCRecruitingNCT06030258Phase 1/2
• Real-World Study on the Efficacy of IBI-322 in Combination With Lenvatinib for the Treatment of Extensive Stage Small Cell Lung CancerRecruitingNCT05991180
• Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid TumorsRecruitingNCT05983432Phase 1
• Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT05978284Phase 1/2
• Study of Selinexor Combined With Olaparib in Relapsed/Refractory Extensive Stage Small Cell Lung CancerRecruitingNCT05975944Phase 1/2
• A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerRecruitingNCT05963867Phase 1
• Molecular Analysis and Treatment Options of SCLCRecruitingNCT05945745
• A Phase Ib Study of TQB2450 Combined With Anlotinib in Patients With Limited Stage Small Cell Lung Cancer After First-line Radiotherapy and ChemotherapyRecruitingNCT05942508Phase 1
• A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung CancerRecruitingNCT05924841Phase 2
• A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid TumorsRecruitingNCT05914116Phase 1/2
• MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung CancerRecruitingNCT05903092Phase 2
• A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
• Rapid Autopsy Protocol for Patients With Small Cell Lung CancerRecruitingNCT05889546
• Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
• DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine CancersRecruitingNCT05882058Phase 2
• The IIT Study of Evaluation of P-IL-2 Single Agent and With Anti-PD-1RecruitingNCT05829057Phase 1
• Dose Attenuated Chemotherapy in Compromised Patients With Lung CancerRecruitingNCT05800587Phase 2
• Panomic Approach to Immune-Connected Assays in Small Cell Lung CancerRecruitingNCT05797493
• IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid TumorsRecruitingNCT05780307Phase 1
• Examining Clinical Trial Participation for Small Cell Lung Cancer PatientsNot yet recruitingNCT05769504
• Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell CarcinomaRecruitingNCT05760053Phase 2
• First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLCRecruitingNCT05745350Phase 2
• SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC)RecruitingNCT05731518Phase 1/2
• FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy InductionNot yet recruitingNCT05703997Phase 2
• Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLCNot yet recruitingNCT05668767Phase 2
• A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)RecruitingNCT05652686Phase 1/2
• PCI and Brain MRI Follow-up vs Brain MRI Follow-up Alone in Limited-stage SCLC PatientsRecruitingNCT05651802Not applicable
• TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVORecruitingNCT05628376
• Proteomics in Small Cell Lung CancerRecruitingNCT05623956
• Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRTRecruitingNCT05623267Phase 2/3

← Small Cell Lung Carcinoma overview